Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15 - Yahoo Finance
VLA Stock | EUR 1.83 0.01 0.54% |
About 62% of Valneva SE's investor base is looking to short. The analysis of current outlook of investing in Valneva SE suggests that many traders are alarmed regarding Valneva SE's prospects. The current market sentiment, together with Valneva SE's historical and current headlines, can help investors time the market. In addition, many technical investors use Valneva SE stock news signals to limit their universe of possible portfolio assets.
Valneva |
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15 Yahoo Finance
Read at news.google.com
Valneva SE Fundamental Analysis
We analyze Valneva SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Valneva SE using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Valneva SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Valneva SE is currently under evaluation in target price category among its peers.
Valneva SE Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Valneva SE stock to make a market-neutral strategy. Peer analysis of Valneva SE could also be used in its relative valuation, which is a method of valuing Valneva SE by comparing valuation metrics with similar companies.
Peers
Valneva SE Related Equities
IPH | Innate Pharma | 22.58 | ||||
VALN | Valneva SE | 0.76 | ||||
GNFT | Genfit | 1.40 | ||||
NANO | Nanobiotix | 2.13 | ||||
DBV | DBV Technologies | 5.71 |
Complementary Tools for Valneva Stock analysis
When running Valneva SE's price analysis, check to measure Valneva SE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Valneva SE is operating at the current time. Most of Valneva SE's value examination focuses on studying past and present price action to predict the probability of Valneva SE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Valneva SE's price. Additionally, you may evaluate how the addition of Valneva SE to your portfolios can decrease your overall portfolio volatility.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Global Correlations Find global opportunities by holding instruments from different markets |